Procysbi Approval History
FDA Approved: Yes (First approved April 30, 2013)
Brand name: Procysbi
Generic name: cysteamine bitartrate
Dosage form: Delayed-Release Capsules
Company: Raptor Pharmaceutical Corp.
Treatment for: Nephropathic Cystinosis
Procysbi (cysteamine bitartrate) is a cystine depleting agent indicated for the treatment of nephropathic cystinosis.
Development History and FDA Approval Process for Procysbi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.